RIP-1 was expressed in the cytoplasm but not in the nuclei, whereas phospho-RIP-1 was mostly expressed in the nuclei after treatment with exosomes derived from NAFLD patients, but not from healthy subjects, supporting the hypothesis that ripoptosome complex phosphorylation and nuclear translocation are required for phospho-RIP-1 to exert its function in the necroptotic pathway [14]. Here, RIPK1 is linked to metabolic dysfunction-associated steatotic liver disease.